<DOC>
	<DOCNO>NCT00101608</DOCNO>
	<brief_summary>The purpose clinical research study learn vinflunine shrink slow growth cancer increase survival patient transitional cell carcinoma urothelium . The safety treatment also study .</brief_summary>
	<brief_title>Vinflunine Patients With Locally Advanced Metastatic Transitional Cell Carcinoma Urothelium</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Transitional Cell</mesh_term>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Ureteral Neoplasms</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<criteria>Clinical diagnosis transitional cell carcinoma urothelium locally advanced metastatic ( i.e . patient candidate local/regional control disease ) . Relapse progression within 12.5 month prior cisplatin carboplatin contain chemotherapy regimen . Adequate performance status ( Karnofsky great equal 80 ) . Receipt 1 prior chemotherapy regimen set . Prior discontinuation platinum due solely toxicity . Current neuropathy great equal CTC grade 2 . Prior radiation great equal 30 % bone marrow . Inadequate hematologic function : ANC &lt; 1,500 cells/mm3 , Platelet &lt; 100,000 cells/mm3 . Inadequate hepatic function : total bilirubin &gt; 1.5 time ULN , ALT/AST &gt; 2.5 time ULN &gt; 5 time ULN case liver metastasis . Inadequate renal function : creatinine clearance &lt; 20 ml/min . Prior allergy vincaalkaloid .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2008</verification_date>
	<keyword>urothelium</keyword>
</DOC>